Galapagos | GLPG

Stock Price
28.44
Daily Change
1.84 6.92%
Monthly
0.99%
Yearly
11.53%
Q3 Forecast
28.26

Peers Price Chg Day Year Date
argenx SE 639.80 8.40 1.33% 31.21% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GRIFOLS 12.30 0.02 0.16% 32.17% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Merck 109.55 1.05 0.97% -35.52% Sep/06
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
UCB 206.90 2.30 1.12% 28.99% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
NL25 899 -1.51 -0.17% 2.20% Sep/05
BE20 4769 23.50 0.50% 14.34% Sep/05
EU100 1582 -4.83 -0.30% 9.89% Sep/05

Galapagos traded at 28.44 this Saturday September 6th, increasing 1.84 or 6.92 percent since the previous trading session. Looking back, over the last four weeks, Galapagos gained 0.99 percent. Over the last 12 months, its price rose by 11.53 percent. Looking ahead, we forecast Galapagos to be priced at 28.26 by the end of this quarter and at 27.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.